董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William K. Heiden | -- | Chairman of the Board | -- | 14.50万美元 | 20.83 | 2025-12-31 |
| Meenu Chhabra Karson | -- | Independent Director | -- | 8.02万美元 | 18.97 | 2025-12-31 |
| Federica O'Brien | -- | Independent Director | -- | 11.05万美元 | 22.43 | 2025-12-31 |
| Scott T. Jackson | -- | Independent Director | -- | 8.19万美元 | 17.03 | 2025-12-31 |
| Margaret A. Liu | -- | Independent Director | -- | 8.59万美元 | 10.83 | 2025-12-31 |
| Karen Jean Ferrante | 女 | Independent Director | 68 | 8.59万美元 | 19.55 | 2025-12-31 |
| Jay Siegel | -- | Independent Director | -- | 10.63万美元 | 20.50 | 2025-12-31 |
| Edward Hurwitz | 男 | Independent Director | 62 | 8.59万美元 | 19.18 | 2025-12-31 |
| David Stump | 男 | Independent Director | 76 | 9.59万美元 | 15.88 | 2025-12-31 |
| Eric Risser | 男 | Director, President and Chief Executive Officer | 53 | 207.89万美元 | 90.28 | 2025-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Beth Smith | -- | Vice President, Controller, Treasurer and Principal Accounting Officer | -- | 未披露 | 未持股 | 2025-12-31 |
| Jeffrey Stuart Peters | -- | Senior Vice President, General Counsel and Corporate Compliance Officer | -- | 未披露 | 未持股 | 2025-12-31 |
| Thomas Spitznagel | -- | Senior Vice President, Technical Operations | -- | 未披露 | 未持股 | 2025-12-31 |
| James Karrels | 男 | Senior Vice President, Chief Financial Officer and Corporate Secretary | 59 | 114.92万美元 | 96.76 | 2025-12-31 |
| Ezio Bonvini | 男 | Senior Vice President, Research and Chief Scientific Officer | 72 | 122.40万美元 | 95.48 | 2025-12-31 |
| Eric Risser | 男 | Director, President and Chief Executive Officer | 53 | 207.89万美元 | 90.28 | 2025-12-31 |
董事简历
中英对照 | 中文 | 英文- William K. Heiden
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Meenu Chhabra Karson
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Federica O'Brien
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Scott T. Jackson
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Margaret A. Liu
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Karen Jean Ferrante
-
Karen Jean Ferrante曾担任Tokai Pharmaceuticals的首席医疗官和研发主管。在Tokai之前，Ferrante博士曾在Millennium Pharmaceuticals Inc.和母公司Takeda Pharmaceuticals担任多个高级职位，包括肿瘤治疗领域负责人、Takeda Cambridge Site负责人和首席医疗官。Ferrante博士此前曾在辉瑞全球研发和百时美施贵宝担任越来越重要的职务。Ferrante博士拥有乔治城大学的医学博士学位，并在新英格兰女执事医院（现为贝斯以色列女执事医疗中心的一部分）完成了实习和内科住院医师实习，随后获得了血液学和肿瘤学研究金。她目前担任生物制药上市公司Cogent Biosciences（前身为Unum Therapeutics）的董事会成员。她此前曾担任上市生物制药公司Hutch-Med（前身为和黄医药）以及此前上市的生物制药公司普罗基尼克斯制药，Inc.和Baxalta Inc.的董事会成员。她还曾在Kazia Therapeutics的科学顾问委员会（2016-2022年）和延龄草治疗的科学顾问委员会任职，直到2021年被辉瑞收购。
Karen Jean Ferrante served as Chief Medical Officer and Head of Research and Development at Tokai Pharmaceuticals. Prior to Tokai, Dr. Ferrante held several senior level positions at Millennium Pharmaceuticals Inc. and parent company Takeda Pharmaceuticals, including Oncology Therapeutic Area Head, Takeda Cambridge Site Head and Chief Medical Officer. Dr. Ferrante previously held positions of increasing responsibility at Pfizer Global Research and Development and Bristol-Myers Squibb. Dr. Ferrante holds an M.D. from Georgetown University and completed her internship and residency in internal medicine at New England Deaconess Hospital (now part of Beth Israel Deaconess Medical Center) followed by a fellowship in hematology and oncology. She currently serves as a member of the board of Cogent Biosciences (formerly Unum Therapeutics), a publicly traded biopharmaceutical company. She previously served on the board of Hutch-Med (formerly Chi-Med) a publicly traded biopharmaceutical company and Progenics Pharmaceuticals, Inc. and Baxalta Inc., previously publicly traded biopharmaceutical companies. She also served on the scientific advisory board of Kazia Therapeutics (2016-2022) and the Trillium Therapeutics' scientific advisory board until its acquisition by Pfizer in 2021. - Karen Jean Ferrante曾担任Tokai Pharmaceuticals的首席医疗官和研发主管。在Tokai之前，Ferrante博士曾在Millennium Pharmaceuticals Inc.和母公司Takeda Pharmaceuticals担任多个高级职位，包括肿瘤治疗领域负责人、Takeda Cambridge Site负责人和首席医疗官。Ferrante博士此前曾在辉瑞全球研发和百时美施贵宝担任越来越重要的职务。Ferrante博士拥有乔治城大学的医学博士学位，并在新英格兰女执事医院（现为贝斯以色列女执事医疗中心的一部分）完成了实习和内科住院医师实习，随后获得了血液学和肿瘤学研究金。她目前担任生物制药上市公司Cogent Biosciences（前身为Unum Therapeutics）的董事会成员。她此前曾担任上市生物制药公司Hutch-Med（前身为和黄医药）以及此前上市的生物制药公司普罗基尼克斯制药，Inc.和Baxalta Inc.的董事会成员。她还曾在Kazia Therapeutics的科学顾问委员会（2016-2022年）和延龄草治疗的科学顾问委员会任职，直到2021年被辉瑞收购。
- Karen Jean Ferrante served as Chief Medical Officer and Head of Research and Development at Tokai Pharmaceuticals. Prior to Tokai, Dr. Ferrante held several senior level positions at Millennium Pharmaceuticals Inc. and parent company Takeda Pharmaceuticals, including Oncology Therapeutic Area Head, Takeda Cambridge Site Head and Chief Medical Officer. Dr. Ferrante previously held positions of increasing responsibility at Pfizer Global Research and Development and Bristol-Myers Squibb. Dr. Ferrante holds an M.D. from Georgetown University and completed her internship and residency in internal medicine at New England Deaconess Hospital (now part of Beth Israel Deaconess Medical Center) followed by a fellowship in hematology and oncology. She currently serves as a member of the board of Cogent Biosciences (formerly Unum Therapeutics), a publicly traded biopharmaceutical company. She previously served on the board of Hutch-Med (formerly Chi-Med) a publicly traded biopharmaceutical company and Progenics Pharmaceuticals, Inc. and Baxalta Inc., previously publicly traded biopharmaceutical companies. She also served on the scientific advisory board of Kazia Therapeutics (2016-2022) and the Trillium Therapeutics' scientific advisory board until its acquisition by Pfizer in 2021.
- Jay Siegel
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Edward Hurwitz
-
Edward Hurwitz，他一直担任公司董事（2018年11月以来）。他曾担任MPM Capital的董事总经理（2017年1月以来），以及Precision BioVentures的董事总经理（2013年创立公司以来）。在加入MPM Capital之前，他从2002年到2014年12月担任Alta Partners的董事。在加入Alta Partners之前，Hurwitz先生从1997年到2002年担任Affymetrix的高级副总裁兼首席财务官。在任职Affymetrix之前，他是Robertson Stephens & Company和Smith Barney Shearson的生物技术研究分析师，也是Cooley Godward LLP的律师。2008年至2014年，他曾担任上市公司Sunesis Pharmaceuticals的董事；2006年至2014年，他曾担任上市公司Cara Therapeutics的董事。Hurwitz先生担任MacroGenics， Inc.和Applied Genetic Technologies Corporation以及几家私人公司的董事会成员。他持有California大学伯克利分校的法学博士和工商管理硕士学位，以及Cornell大学的分子生物学学士学位。
Edward Hurwitz has served as a director of company since November 2018. Mr. Hurwitz has served as a Managing Director at MPM Capital since January 2017 and as Managing Director of Precision BioVentures since he founded the firm in 2013. Prior to joining MPM Capital, Mr. Hurwitz was a Director at Alta Partners from 2002 through December 2014. Prior to joining Alta Partners, Mr. Hurwitz served as Senior Vice President and CFO of Affymetrix from 1997 to 2002. Prior to his service at Affymetrix, Mr. Hurwitz was a biotechnology research analyst for Robertson Stephens&Company and Smith Barney Shearson and a lawyer at Cooley Godward LLP. Mr. Hurwitz previously served as a director of Sunesis Pharmaceuticals, Inc., a publicly held company, from 2008 to 2014 and as a director of Cara Therapeutics, Inc., a publicly held company, from 2006 to 2014. Mr. Hurwitz serves as a member of the board of directors of MacroGenics, Inc. and Applied Genetic Technologies Corporation and several private companies. Mr. Hurwitz earned his J.D. and M.B.A. degrees from the University of California, Berkeley, and his B.A. in molecular biology from Cornell University. - Edward Hurwitz，他一直担任公司董事（2018年11月以来）。他曾担任MPM Capital的董事总经理（2017年1月以来），以及Precision BioVentures的董事总经理（2013年创立公司以来）。在加入MPM Capital之前，他从2002年到2014年12月担任Alta Partners的董事。在加入Alta Partners之前，Hurwitz先生从1997年到2002年担任Affymetrix的高级副总裁兼首席财务官。在任职Affymetrix之前，他是Robertson Stephens & Company和Smith Barney Shearson的生物技术研究分析师，也是Cooley Godward LLP的律师。2008年至2014年，他曾担任上市公司Sunesis Pharmaceuticals的董事；2006年至2014年，他曾担任上市公司Cara Therapeutics的董事。Hurwitz先生担任MacroGenics， Inc.和Applied Genetic Technologies Corporation以及几家私人公司的董事会成员。他持有California大学伯克利分校的法学博士和工商管理硕士学位，以及Cornell大学的分子生物学学士学位。
- Edward Hurwitz has served as a director of company since November 2018. Mr. Hurwitz has served as a Managing Director at MPM Capital since January 2017 and as Managing Director of Precision BioVentures since he founded the firm in 2013. Prior to joining MPM Capital, Mr. Hurwitz was a Director at Alta Partners from 2002 through December 2014. Prior to joining Alta Partners, Mr. Hurwitz served as Senior Vice President and CFO of Affymetrix from 1997 to 2002. Prior to his service at Affymetrix, Mr. Hurwitz was a biotechnology research analyst for Robertson Stephens&Company and Smith Barney Shearson and a lawyer at Cooley Godward LLP. Mr. Hurwitz previously served as a director of Sunesis Pharmaceuticals, Inc., a publicly held company, from 2008 to 2014 and as a director of Cara Therapeutics, Inc., a publicly held company, from 2006 to 2014. Mr. Hurwitz serves as a member of the board of directors of MacroGenics, Inc. and Applied Genetic Technologies Corporation and several private companies. Mr. Hurwitz earned his J.D. and M.B.A. degrees from the University of California, Berkeley, and his B.A. in molecular biology from Cornell University.
- David Stump
-
David Stump，他曾一直担任公司董事会成员（2010年6月以来）。他最近任职 Human Genome Sciences公司（从1999年11月到2012年12月）。他担任Human Genome Sciences公司（一家生物制药公司）的研究和开发执行副总裁（从2007年5月到2007年12月），药物开发的执行副总裁（从2003年12月到2007年5月），药物开发高级副总裁（从1999年11月到2003年12月）。此前，他曾担任过Genentech公司的数个职位，包括临床研究副总裁，并于1996年被任命为Genentech的领导，负责心血管药物开发活动。他曾担任佛蒙特大学的医学和生物化学副教授。他目前担任 Sunesis Pharmaceuticals公司（上市医药公司）和MacroGenics公司（上市的生物制药公司）的董事会成员。他也服务于厄勒姆学院的董事会。他获得了印第安纳大学的医学博士学位和厄尔罕姆学院的学士学位。他完成了内科，血液学，肿瘤学（爱荷华州立大学董事会认证在所有三个领域）的住院实习。
David Stump has been a Director since October 2015. From 1999 to 2012, Dr. Stump was with Human Genome Sciences, Inc., a biopharmaceutical company, as Executive Vice President, Research and Development from 2007 to 2012, Executive Vice President, Drug Development from 2003 to 2007 and Senior Vice President, Drug Development from 1999 to 2003. Prior to joining Human Genome Sciences, Dr. Stump held roles of increasing responsibility at Genentech, Inc., a biopharmaceutical company, from 1989 to 1999, including Vice President, Clinical Research and Genentech Fellow. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. Dr. Stump has served as a director at MacroGenics, Inc., a publicly held biopharmaceutical company, since 2013. He also currently serves on the board of trustees of Earlham College. Dr. Stump previously served as a director at Sunesis Pharmaceuticals, Inc. from 2006 to 2021, Portola Pharmaceuticals, Inc. from 2015 to 2020 and Dendreon Corporation, a biotechnology company, from 2010 to 2015. - David Stump，他曾一直担任公司董事会成员（2010年6月以来）。他最近任职 Human Genome Sciences公司（从1999年11月到2012年12月）。他担任Human Genome Sciences公司（一家生物制药公司）的研究和开发执行副总裁（从2007年5月到2007年12月），药物开发的执行副总裁（从2003年12月到2007年5月），药物开发高级副总裁（从1999年11月到2003年12月）。此前，他曾担任过Genentech公司的数个职位，包括临床研究副总裁，并于1996年被任命为Genentech的领导，负责心血管药物开发活动。他曾担任佛蒙特大学的医学和生物化学副教授。他目前担任 Sunesis Pharmaceuticals公司（上市医药公司）和MacroGenics公司（上市的生物制药公司）的董事会成员。他也服务于厄勒姆学院的董事会。他获得了印第安纳大学的医学博士学位和厄尔罕姆学院的学士学位。他完成了内科，血液学，肿瘤学（爱荷华州立大学董事会认证在所有三个领域）的住院实习。
- David Stump has been a Director since October 2015. From 1999 to 2012, Dr. Stump was with Human Genome Sciences, Inc., a biopharmaceutical company, as Executive Vice President, Research and Development from 2007 to 2012, Executive Vice President, Drug Development from 2003 to 2007 and Senior Vice President, Drug Development from 1999 to 2003. Prior to joining Human Genome Sciences, Dr. Stump held roles of increasing responsibility at Genentech, Inc., a biopharmaceutical company, from 1989 to 1999, including Vice President, Clinical Research and Genentech Fellow. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. Dr. Stump has served as a director at MacroGenics, Inc., a publicly held biopharmaceutical company, since 2013. He also currently serves on the board of trustees of Earlham College. Dr. Stump previously served as a director at Sunesis Pharmaceuticals, Inc. from 2006 to 2021, Portola Pharmaceuticals, Inc. from 2015 to 2020 and Dendreon Corporation, a biotechnology company, from 2010 to 2015.
- Eric Risser
-
Eric Risser于2009年加入MacroGenics，领导其业务发展工作，并从那时起承担了越来越多的运营和战略责任，最近担任首席运营官。在加入MacroGenics之前，Risser先生曾在Johnson & Johnson担任企业发展高级总监，在那里他领导了多项许可和收购交易。在职业生涯早期，他在投资银行、风险资本和战略咨询等领域担任过各种生命科学职位。他持有Stanford大学的工商管理硕士学位和Yale大学的学士学位。
Eric Risser,joined MacroGenics in 2009 to lead its business development efforts and has assumed roles of increasing operational and strategic responsibility since that time, most recently as Chief Operating Officer. Prior to joining MacroGenics, Mr. Risser worked at Johnson&Johnson as Senior Director in Corporate Development, where he led multiple licensing and acquisition transactions. Earlier in his career, he held a variety of life science roles across investment banking, venture capital, and strategy consulting. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University. - Eric Risser于2009年加入MacroGenics，领导其业务发展工作，并从那时起承担了越来越多的运营和战略责任，最近担任首席运营官。在加入MacroGenics之前，Risser先生曾在Johnson & Johnson担任企业发展高级总监，在那里他领导了多项许可和收购交易。在职业生涯早期，他在投资银行、风险资本和战略咨询等领域担任过各种生命科学职位。他持有Stanford大学的工商管理硕士学位和Yale大学的学士学位。
- Eric Risser,joined MacroGenics in 2009 to lead its business development efforts and has assumed roles of increasing operational and strategic responsibility since that time, most recently as Chief Operating Officer. Prior to joining MacroGenics, Mr. Risser worked at Johnson&Johnson as Senior Director in Corporate Development, where he led multiple licensing and acquisition transactions. Earlier in his career, he held a variety of life science roles across investment banking, venture capital, and strategy consulting. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.
高管简历
中英对照 | 中文 | 英文- Beth Smith
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jeffrey Stuart Peters
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Thomas Spitznagel
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- James Karrels
James Karrels，高级副总裁、首席财务官兼公司秘书，于2008年5月加入公司，拥有超过20年的财务经验，其中包括behalf of, life sciences companies工作约15年。在加入之前，他在Jazz Pharmaceuticals， Inc.任职，最近担任财务执行董事，负责公司的财务规划和分析以及投资者关系活动。在加入Jazz Pharmaceuticals之前，他在Merrill Lynch的投资银行集团工作了11年，最近担任全球医疗保健集团的董事。他持有Stanford大学的工商管理硕士学位和Notre Dame大学的工商管理硕士学位。
James Karrels, Senior Vice President, Chief Financial Officer and Corporate Secretary, joined in May 2008 and has over 20 years of experience in finance, including approximately 15 years working for, or on behalf of, life sciences companies. Prior to joining, he was at Jazz Pharmaceuticals, Inc., most recently serving as Executive Director of Finance, where he was responsible for the company's financial planning and analysis and investor relations activities. Prior to joining Jazz Pharmaceuticals, Mr. Karrels spent 11 years in the Investment Banking Group at Merrill Lynch, most recently serving as a Director in the Global Healthcare Group. Mr. Karrels holds an M.B.A. from Stanford University and a B.B.A. from the University of Notre Dame.- James Karrels，高级副总裁、首席财务官兼公司秘书，于2008年5月加入公司，拥有超过20年的财务经验，其中包括behalf of, life sciences companies工作约15年。在加入之前，他在Jazz Pharmaceuticals， Inc.任职，最近担任财务执行董事，负责公司的财务规划和分析以及投资者关系活动。在加入Jazz Pharmaceuticals之前，他在Merrill Lynch的投资银行集团工作了11年，最近担任全球医疗保健集团的董事。他持有Stanford大学的工商管理硕士学位和Notre Dame大学的工商管理硕士学位。
- James Karrels, Senior Vice President, Chief Financial Officer and Corporate Secretary, joined in May 2008 and has over 20 years of experience in finance, including approximately 15 years working for, or on behalf of, life sciences companies. Prior to joining, he was at Jazz Pharmaceuticals, Inc., most recently serving as Executive Director of Finance, where he was responsible for the company's financial planning and analysis and investor relations activities. Prior to joining Jazz Pharmaceuticals, Mr. Karrels spent 11 years in the Investment Banking Group at Merrill Lynch, most recently serving as a Director in the Global Healthcare Group. Mr. Karrels holds an M.B.A. from Stanford University and a B.B.A. from the University of Notre Dame.
- Ezio Bonvini
Ezio Bonvini担任研究高级副总裁，他于2003年6月加入。从1985年到2003年，他在FDA的生物制品评价和研究中心或CBER工作，负责调节治疗性单克隆抗体和其他蛋白质，最终担任单克隆抗体部门代理副主任和免疫生物学实验室主管。从1982年到1984年，他是美国国立卫生研究院的美国国家癌症研究所客座研究员。他拥有意大利热那亚Scientific Lyceum的理科文凭，热那亚大学（University of Genoa）医学院的硕士和临床血液学专业认证。
Ezio Bonvini, Senior Vice President, Research, joined in June 2003. From 1985 to 2003 Dr. Bonvini was with the FDA in the Center for Biologics Evaluation and Research, or CBER, which is responsible for regulating therapeutic monoclonal antibodies and other proteins, ultimately serving as Acting Deputy Director, Division of Monoclonal Antibodies and Chief, Laboratory of Immunobiology. From 1982 to 1984 Dr. Bonvini was a Visiting Fellow at the National Cancer Institute at the National Institutes of Health. Dr. Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy, and his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine.- Ezio Bonvini担任研究高级副总裁，他于2003年6月加入。从1985年到2003年，他在FDA的生物制品评价和研究中心或CBER工作，负责调节治疗性单克隆抗体和其他蛋白质，最终担任单克隆抗体部门代理副主任和免疫生物学实验室主管。从1982年到1984年，他是美国国立卫生研究院的美国国家癌症研究所客座研究员。他拥有意大利热那亚Scientific Lyceum的理科文凭，热那亚大学（University of Genoa）医学院的硕士和临床血液学专业认证。
- Ezio Bonvini, Senior Vice President, Research, joined in June 2003. From 1985 to 2003 Dr. Bonvini was with the FDA in the Center for Biologics Evaluation and Research, or CBER, which is responsible for regulating therapeutic monoclonal antibodies and other proteins, ultimately serving as Acting Deputy Director, Division of Monoclonal Antibodies and Chief, Laboratory of Immunobiology. From 1982 to 1984 Dr. Bonvini was a Visiting Fellow at the National Cancer Institute at the National Institutes of Health. Dr. Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy, and his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine.
- Eric Risser
Eric Risser于2009年加入MacroGenics，领导其业务发展工作，并从那时起承担了越来越多的运营和战略责任，最近担任首席运营官。在加入MacroGenics之前，Risser先生曾在Johnson & Johnson担任企业发展高级总监，在那里他领导了多项许可和收购交易。在职业生涯早期，他在投资银行、风险资本和战略咨询等领域担任过各种生命科学职位。他持有Stanford大学的工商管理硕士学位和Yale大学的学士学位。
Eric Risser,joined MacroGenics in 2009 to lead its business development efforts and has assumed roles of increasing operational and strategic responsibility since that time, most recently as Chief Operating Officer. Prior to joining MacroGenics, Mr. Risser worked at Johnson&Johnson as Senior Director in Corporate Development, where he led multiple licensing and acquisition transactions. Earlier in his career, he held a variety of life science roles across investment banking, venture capital, and strategy consulting. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.- Eric Risser于2009年加入MacroGenics，领导其业务发展工作，并从那时起承担了越来越多的运营和战略责任，最近担任首席运营官。在加入MacroGenics之前，Risser先生曾在Johnson & Johnson担任企业发展高级总监，在那里他领导了多项许可和收购交易。在职业生涯早期，他在投资银行、风险资本和战略咨询等领域担任过各种生命科学职位。他持有Stanford大学的工商管理硕士学位和Yale大学的学士学位。
- Eric Risser,joined MacroGenics in 2009 to lead its business development efforts and has assumed roles of increasing operational and strategic responsibility since that time, most recently as Chief Operating Officer. Prior to joining MacroGenics, Mr. Risser worked at Johnson&Johnson as Senior Director in Corporate Development, where he led multiple licensing and acquisition transactions. Earlier in his career, he held a variety of life science roles across investment banking, venture capital, and strategy consulting. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.